DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
Trusted Resources: News & Events
Latest announcements and gatherings
TUESDAY, JUNE 18, 2019 | 2:30 – 3:30 PM
DIRKSEN SENATE OFFICE BUILDING, ROOM G50
RSVP: Betsy Foss-Campbell, email@example.com
Join us for updates on Gene therapy approaches presented by prominent scientists in the field
How policymakers can support the development of treatment options for sickle cell disease
Tim Scott, United States Senator
Francesca Cook, MPH, Government Relations Committee member, ASGCT; Senior Director, Pricing and Market Access, REGENXBIO
Julie Kanter, MD, Director of Adult Sickle Cell Program; Associate Professor of Hematology and Oncology, University of Alabama at Birmingham
Punam Malik, MD, Professor of Pediatrics, Marjorie Johnson Chair of Gene and Cell Therapy, Director, Cincinnati Comprehensive Sickle Cell Center; Cancer and Blood Disease Institute, Cincinnati Children’s Hospital
Rodrick Murray, Patient advocate providing a personal story on gene therapy’s value for treating sickle cell disease
Matthew Porteus, MD, PhD, Professor of Pediatrics (Stem Cell Transplantation), Stanford University
David Williams, MD, Senior Vice President and Chief Scientific Officer, Boston Children’s Hospital; Chief, Hematology/Oncology, Boston Children’s Hospital; President, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Leland Fikes Professor of Pediatrics, Harvard Medical School
How can policymakers help support the development of gene therapies for sickle cell disease?
- Support the need for robust NIH research funding
- Support appropriations to the sickle cell disease prevention and treatment program and implementation of new surveillance and screening authorities passed in 2018
- Enable novel payment models for approved gene therapies
Hosted in partnership with the Pediatric Hospital Sickle Cell Disease Collaborative and American Society of Gene & Cell Therapy, American Society of Hematology, American Society for Transplantation and Cellular Therapy, and Sickle Cell Disease Association of America, Inc.
This event has ended.
videos & visualsSickle Cell Emergency Room Care: From Patients to Providershttps://www.youtube.com/watch?time_conti...
news & eventsNFL Broadcaster Solomon Wilcots and Emmaus Life Sciences Kick Off “Sideline Sickle Cell” Campaign during...Emmy Award-winning NFL broadcaster Solom...
news & eventsSCD Patients Receiving Hydroxyurea in the U.S. Still Face Many ChallengesPeople with sickle cell disease (SCD) tr...
videos & visualsWorld Sickle Cell Day: Sisters Living With Sickle Cell, Hoping for a Curehttps://www.youtube.com/watch?v=y3Bg0RJv...
people & placesAshley Singleton, MPHAshley Singleton is a Program and Resear...
people & placesJohn F. Tisdale, MDJohn F. Tisdale, MD graduated from the C...
news & eventsCharlotte 13-Year-Old With Sickle Cell Plays Lead Role in Broadway’s ‘Lion King’"The Lion King" opens Wednesday night at...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.